14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies

SAE Media Group8 - 9 February 2023, London, United Kingdom.
RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. With COVID-19 rapidly accelerating the RNA landscape through massive regulatory successes, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, there has been considerable progress in the development of RNA medicines and a major expansion of the RNA-therapeutics field.

In 2023 we will see the return of SAE's RNA Therapeutics conference to a live in-person event, showcasing an update on mRNA therapeutic applications, coupled with an industry outlook of the field. We will also explore the latest trends in novel RNA therapies, including developments in AI modelling and small molecule modulation of RNA. Further topics to be examined comprise of novel RNA modalities encompassing self-amplifying RNA, saRNA, circular RNA, lnc RNA and many more.

Don't miss this unmissable opportunity to network with the pharma and biotech community of global experts in the UK and Europe; the two-day agenda offers you peer-to-peer networking with Directors of novel RNA therapies, CEOs, Senior and expert scientists, Chief Medical Officers, Senior Vice Presidents and many more.

Benefits of attending

  • Explore how mRNA leads the way in the genetic medicine space as the next generation of novel drug modalities
  • Investigate the latest trends in AI drug discovery as a tool for designing novel RNA based therapeutics
  • Enhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech, Neuway Pharma and Ethris GmbH
  • Engage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory, neurodegenerative, and infectious diseases

Who should attend

  • Directors of novel RNA therapies
  • CEOs
  • Senior and expert scientists
  • Chief Medical Officers
  • Chief Technical Officers
  • Senior Vice Presidents
  • Global Heads of mRNA R&D
  • Global Medical Directors
  • Heads of Translational Medicine
  • Director, Clinical Pharmacology
  • Global Head of RNA and Targeted Therapeutics
  • Clinical Science Director
  • Head of Biology
  • Director, Genetic Medicine
  • Associate Director

Early-bird rates

  • Book by 30th November and save £200
  • Book by 16th December and save £100

For further information and to register, please visit:
http://www.therapeutics-rna.com

About SAE Media Group

SAE Media Group Conferences, based in London, connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges.

Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences.

SAE Media Group (SMG), an subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.

SAE Media Group is comprised of two synergistic organizations:

  • SMG Conferences, based in London, produces over 60 high-level networking events worldwide, concentrating on the Aerospace, Defense, Pharmaceutical, and Medic al industries. These events bring together senior government and industry executives/program managers to share knowledge and collaborate on key technology topics including military space, unmanned and autonomous systems, microbiology, biosensors, and much more. SMG’s flagship event, Global MilSatCom, is the world’s premier conference for the military satellite communications market.
  • SMG Media, headquartered in New York City, offers a diverse multimedia network of engineering magazines, e-newsletters, web sites, webcasts, special reports, and custom marketing services. Primary areas of focus include the Aerospace/Defense, Automotive, Commercial Vehicle, Electronics, and Medical sectors, with extensive coverage of cross-industry technologies including batteries/energy storage, sensors, photonics and imaging, advanced manufacturing, robotics, and motion control.

Most Popular Now

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...